Literature DB >> 27296321

Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.

Claudia Bracaglia1, Kathy de Graaf2, Denise Pires Marafon1, Florence Guilhot2, Walter Ferlin2, Giusi Prencipe1, Ivan Caiello1, Sergio Davì3, Grant Schulert4, Angelo Ravelli3, Alexei A Grom4, Cristina de Min2, Fabrizio De Benedetti1.   

Abstract

OBJECTIVES: Interferon-γ (IFNγ) is the pivotal mediator in murine models of primary haemophagocytic lymphohistiocytosis (pHLH). Given the similarities between primary and secondary HLH (sec-HLH), including macrophage activation syndrome (MAS), we investigate the involvement of the IFNγ pathway in MAS by evaluating levels of IFNγ and of the induced chemokines, and their relation with laboratory parameters of MAS in systemic juvenile idiopathic arthritis (sJIA) patients with MAS and in a murine MAS model.
METHODS: The Luminex multiplexing assay was used to assess serum levels of interleukin (IL)-1β, IL-6, IFNγ and of the IFNγ-induced chemokines CXCL9, CXCL10 and CXCL11 in patients with sec-HLH (n=11) and in patients with sJIA (n=54), of whom 20 had active MAS at sampling. Expression of IFNγ-induced chemokines was assessed in IL-6 transgenic mice in which MAS is induced by TLR4 stimulation with lipopolysaccharide.
RESULTS: Levels of IFNγ and of IFNγ-induced chemokines were markedly elevated during active MAS and sec-HLH and were significantly higher in patients with MAS compared with active sJIA without MAS. Levels in patients with active sJIA without MAS were comparable to those of patients with clinically inactive sJIA. During MAS, ferritin and alanine transferase levels and neutrophil and platelet counts were significantly correlated with serum levels of IFNγ and CXCL9. In murine MAS, serum levels of ferritin were significantly correlated with mRNA levels of Cxcl9 in liver and spleen.
CONCLUSIONS: The high levels of IFNγ and of IFNγ-induced chemokines and their correlation with the severity of laboratory abnormalities of MAS suggest a pivotal role of IFNγ in MAS. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Chemokines; Cytokines; Inflammation; Juvenile Idiopathic Arthritis

Mesh:

Substances:

Year:  2016        PMID: 27296321     DOI: 10.1136/annrheumdis-2015-209020

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  76 in total

Review 1.  The rheumatology/hematology interface: CAPS and MAS diagnosis and management.

Authors:  John M Gansner; Nancy Berliner
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections.

Authors:  Dana T Lounder; Qiong Bin; Cristina de Min; Michael B Jordan
Journal:  Blood Adv       Date:  2019-01-08

Review 3.  Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach.

Authors:  Peter A Nigrovic; Pui Y Lee; Hal M Hoffman
Journal:  J Allergy Clin Immunol       Date:  2020-11       Impact factor: 10.793

4.  Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.

Authors:  Asra Ahmed; Samuel A Merrill; Fares Alsawah; Paula Bockenstedt; Erica Campagnaro; Sumana Devata; Scott D Gitlin; Mark Kaminski; Alice Cusick; Tycel Phillips; Suman Sood; Moshe Talpaz; Albert Quiery; Philip S Boonstra; Ryan A Wilcox
Journal:  Lancet Haematol       Date:  2019-09-16       Impact factor: 18.959

5.  Weathering the storm: Improving therapeutic interventions for cytokine storm syndromes by targeting disease pathogenesis.

Authors:  Lehn K Weaver; Edward M Behrens
Journal:  Curr Treatm Opt Rheumatol       Date:  2017-02-07

6.  Combining multiple biomarkers differentiates between active SJIA, SJIA-MAS and EBV-HLH.

Authors:  L K Weaver
Journal:  Clin Exp Immunol       Date:  2017-10-26       Impact factor: 4.330

Review 7.  Proliferation through activation: hemophagocytic lymphohistiocytosis in hematologic malignancy.

Authors:  Eric J Vick; Kruti Patel; Philippe Prouet; Mike G Martin
Journal:  Blood Adv       Date:  2017-05-09

8.  Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome.

Authors:  Eric S Weiss; Charlotte Girard-Guyonvarc'h; Dirk Holzinger; Adriana A de Jesus; Zeshan Tariq; Jennifer Picarsic; Eduardo J Schiffrin; Dirk Foell; Alexei A Grom; Sandra Ammann; Stephan Ehl; Tomoaki Hoshino; Raphaela Goldbach-Mansky; Cem Gabay; Scott W Canna
Journal:  Blood       Date:  2018-01-11       Impact factor: 22.113

9.  Brief Report: Interferon-γ-Mediated Immunopathology Potentiated by Toll-Like Receptor 9 Activation in a Murine Model of Macrophage Activation Syndrome.

Authors:  Lehn K Weaver; Niansheng Chu; Edward M Behrens
Journal:  Arthritis Rheumatol       Date:  2018-11-24       Impact factor: 10.995

10.  Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors.

Authors:  Grant S Schulert; Shima Yasin; Brenna Carey; Claudia Chalk; Thuy Do; Andrew H Schapiro; Ammar Husami; Allen Watts; Hermine I Brunner; Jennifer Huggins; Elizabeth D Mellins; Esi M Morgan; Tracy Ting; Bruce C Trapnell; Kathryn A Wikenheiser-Brokamp; Christopher Towe; Alexei A Grom
Journal:  Arthritis Rheumatol       Date:  2019-10-01       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.